Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Pluristem Therapeutics Stock Quote

Pluristem Therapeutics (NASDAQ: PSTI)

$5.59
(-1.4%)
-$0.08
Price as of April 16, 2024, 10:35 a.m. ET

Pluristem Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
PSTI -22.48% -87.56% -34.09% -100%
S&P +22.34% +74.52% +11.78% +475%

Pluristem Therapeutics Company Info

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.